US Edition
Nektar Therapeutics Is Up 150%: What’s Happening With NKTR Stock?
- Nektar Therapeutics announced positive 16-week Phase 2b REZOLVE-AD results for rezpegaldesleukin treating moderate-to-severe atopic dermatitis on Tuesday.
- The study included 393 participants and focused on assessing improvements in atopic dermatitis severity using the EASI scoring system, comparing the effects of the treatment to a placebo.
- All three doses met primary and key secondary endpoints, showing 53% to 61% symptom improvement and significant reductions in itch and skin severity.
- Nektar's stock surged over 100% Tuesday, reaching $20 per share, though analyst Andy Hsieh called this a "valuation normalization event" rather than a sign of differentiated value.
- The results position Nektar as an attractive acquisition target with peak sales potential exceeding $2 billion, but investors still face risks from future clinical and regulatory hurdles.
22 Articles
22 Articles
Nektar’s Novel Eczema Drug Meets Trial Goals, But Differentiation From Dupixent Remains Unclear
Nektar Therapeutics’ biologic drug rezpegaldesleukin take a new approach to atopic dermatitis, or eczema, stimulating proliferation of immune cells that tamp down excessive immune responses. The drug met the goals of a Phase 2b study, but analysts note that cross-trial measures show those results are short of the marks achieved by Dupixent, the top biologic for atopic dermatitis. The post Nektar’s Novel Eczema Drug Meets Trial Goals, But Differe…
Nektar Therapeutics Soars 86% After Eczema Drug Hits Midstage Trial Goals
Nektar Therapeutics (NKTR) saw its stock surge 86% Tuesday morning after reporting strong midstage trial results for its experimental eczema treatment, rezpegaldesleukin. Shares opened at a seven-month high, after initially showing a triple-digit gain in premarket trading. In the Phase 2b study, patients received three under-the-skin injections of rezpegaldesleukin over 16 weeks. The treatment delivered a 53% to 61% improvement in eczema symptom…
Coverage Details
Bias Distribution
- 73% of the sources are Center
To view factuality data please Upgrade to Premium
